National Institute of Allergy & Infectious Diseases (NIAID)
31 Center Drive MSC 2520
Building 31, Room 7A-50
267 articles with National Institute of Allergy & Infectious Diseases (NIAID)
Fauci E-mails Raise Critical Questions, States the Association of American Physicians and Surgeons (AAPS)
Controversy has erupted concerning the thousands of emails to and from Dr. Anthony Fauci that were released in response to Freedom of Information Act requests from Buzzfeed and the Washington Post.
Several biotech executives provided their thoughts on lessons learned from the pandemic and what they hope or expect to see moving forward in the industry.
When the pandemic hit, many companies diverted resources aimed at HIV to COVID-19, which ended up pausing some research efforts.
Spero Therapeutics Awarded up to $23 Million by the National Institute of Allergy and Infectious Diseases to Support the Development of SPR206
The National Institute of Allergy and Infectious Diseases will fund the continued clinical development of product candidate SPR206
4/20/2021Please check out the biopharma industry's COVID-19 stories that are trending for April 20, 2021.
Moderna, Inc. announced that the Company has shipped the 100-millionth dose of its COVID-19 vaccine to the U.S. Government. More than 67 million doses of the Moderna COVID-19 Vaccine have been administered in the U.S., according to the U.S. Centers for Disease Control and Prevention.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 23, 2021.
Aridis Pharmaceuticals Provides Multiple Program Updates Including the Addition of a Second Inhaled Antibody to Neutralize Newly Emerging COVID-19 Mutated Variants
National Institute of Allergy and Infectious Disease (NIAID) and the Coronavirus Immunotherapy Consortium (CoVIC) are providing preclinical services support to accelerate development
ATCC joins National Institute of Allergy and Infectious Diseases' team working on preclinical services for HIV therapeutics
Celdara Medical and the University of Vermont Secure NIH Funding to Improve Pandemic Preparedness and Response
Celdara Medical, LLC announced that the National Institute of Allergy and Infectious Disease of the National Institutes of Health has awarded it a two-year Small Business Technology Transfer Research grant to fund the development of a novel, broad-spectrum therapeutic/prophylactic against RNA viruses, including SARS-CoV-2, SARS, Ebola, influenza, and pathogenic arenaviruses.
Gritstone Advances Second Generation COVID-19 Vaccine “CORAL” Program with Support from NIAID; Program has Potential to Protect Against Mutant Variants of SARS-CoV-2
Gritstone Oncology, Inc., a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, announced that it is advancing development of a second generation vaccine against SARS-CoV-2, the virus that causes COVID-19, with potential for both prolonged protection and potency against Spike mutants.
Jaguar Health Subsidiary Receiving Preclinical Services from the NIAID for New Preclinical Study Initiated January 6, 2021 for Lechlemer Plant-Based Drug Candidate for the Symptomatic Relief of Diarrhea from Cholera
Jaguar Health, Inc. announced that the 28-day preclinical toxicology and safety study in dogs began today, January 6, 2021, to support development of lechlemer, the second generation, plant-based anti-secretory drug candidate of Napo Pharmaceuticals, Jaguar's wholly owned subsidiary, for the symptomatic relief of diarrhea from cholera.
Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health will join the University of Chicago Harris School of Public Policy on March 4 for a conversation hosted by its dean, Katherine Baicker, who will award Dr. Fauci the 2020 Harris Dean's Award.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 8, 2020.
Researchers with the U.S. National Institutes of Allergy and Infectious Diseases (NIAID) published a letter in The New England Journal of Medicine describing the three-month immunogenicity levels in Moderna’s mRNA-1273 vaccine.
Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study
Moderna intends to submit for an Emergency Use Authorization (EUA) with U.S. FDA in the coming weeks and expects the EUA to be based on the final analysis of 151 cases and a median follow-up of more than 2 months
Eli Lilly is continuing their other trial in mild-to-moderate COVID-19 patients and stated they “remain confident … that bamlanivimab monotherapy may prevent progression of disease for those earlier in the course of COVID-19.”
National Institutes of Health Launches its ACTIV-5 “Big Effect Trial” Evaluating Humanigen’s Lenzilumab™ as Potential COVID-19 Therapy
Lenzilumab among the promising agents selected for ACTIV program from pool of approximately 400 candidate agents
The trial, part of a collaboration with U.S. government agencies including BARDA, the FDA and the NIH, will evaluate the safety, efficacy and tolerability of the anti-SARS-CoV-2 hyperimmune globulin that, if proven safe and effective, could be a potential treatment for COVID-19
Indee Labs announces a grant award from the National Institute of Allergy and Infectious Diseases to develop the µVS Delivery SystemTM for modified regulatory T cells